Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

News · November 11, 2022

COSA 2022: Pembrolizumab Combo Aids Survival in Advanced Cervical Cancer

Pembrolizumab plus standard platinum-based chemo with or without bevacizumab could provide new standard of care in persistent, recurrent, or metastatic cervical cancer

PracticeUpdate Editorial Team


Further Reading